PharmaShots Weekly Snapshot (May 04-08, 2020)

1.Fitbit Launches Heart Study to Validate its Wearable Technology for Identifying Atrial Fibrillation

Published: May 06, 2020 | Tags: Fitbit, Launches, Heart Study, Validate, Wearable Technology, Identifying, Atrial Fibrillation

2.  Celltrion Launches Remsima SC (biosimilar, infliximab) for the Treatment of Autoimmune Diseases in the Netherlands

Published: May 07, 2020 | Tags: Celltrion, Launches, Remsima SC, biosimilar, infliximab, Treatment, Autoimmune Diseases,  Netherlands

3.  GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with COVID-19

Published: May 06, 2020 | Tags: GSK, Evaluate, Otilimab, Treating, Pneumonia, Associated, COVID-19

4. CoVIg-19 Plasma Alliance to Initiate Clinical Study Evaluating Hyperimmune Therapy for COVID-19 by Summer 2020

Published: May 07, 2020 | Tags: CoVIg-19 Plasma Alliance, Initiate, Clinical Study, Evaluating, Hyperimmune Therapy, COVID-19, Summer 2020

5.  Moderna Anticipates the Initiation of P-III Study of mRNA-1273 for COVID-19 by Early Summer

Published: May 07, 2020 | Tags: Moderna, Anticipates, Initiation, P-III, Study, mRNA-1273, COVID-19, Early Summer

6.  Gilead’s Veklury (remdesivir) Receives MHLW’s Approval for Patients with Severe COVID-19 in Japan

Published: May 07, 2020 | Tags: Gilead, Veklury, remdesivir, Receives, MHLW, Approval, Patients, Severe, COVID-19, Japan

7.  Laurent Receives Health Canada’s Approval to Initiate P-II RESOLUTION Study Evaluating LAU-7b for COVID-19

Published: May 06, 2020 | Tags: Laurent, Receives, Health Canada, Approval, Initiate, P-II, RESOLUTION, Study, Evaluating, LAU-7b, COVID-19

8. Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study for Mild-To-Moderate Plaque Psoriasis

Published: May 06, 2020 | Tags: Amgen, Reports, Results, Otezla, apremilast, P-III, ADVANCE, Study, Mild-To-Moderate, Plaque Psoriasis

9. Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar, ranibizumab) in the US and Canada

Published: May 06, 2020 | Tags: Bausch + Lomb, Signs, Exclusive, License Agreement, STADA, Xbrane, Xlucane, biosimilar, ranibizumab, US, Canada

10. Novartis and Incyte’s Tabrecta (capmatinib, INC280) Receives the US FDA’s Approval for Metastatic Non-Small Cell Lung Cancer with METex14

Published: May 06, 2020 | Tags: Novartis, Incyte, Tabrecta, capmatinib, INC280, Receives, US, FDA, Approval, Metastatic Non-Small Cell Lung Cancer, METex14

11. PTC Therapeutics to Acquire Censa Pharmaceuticals to Bolster its Rare Disease Portfolio

Published: May 06, 2020 | Tags: PTC Therapeutics, Acquire, Censa Pharmaceuticals, Bolster, Rare Disease Portfolio

12. Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a P-II Study as 2L Treatment for Advanced Basal Cell Carcinoma

Published: May 05, 2020 | Tags: Sanofi, Regeneron, Report, Results, Libtayo, cemiplimab, P-II, Study, 2L, Treatment, Advanced Basal Cell Carcinoma

13. Bavarian Nordic Collaborates with AdaptVac to Advance COVID-19 Vaccine Program

Published: May 06, 2020 | Tags: Bavarian Nordic, Collaborates, AdaptVac, Advance, COVID-19, Vaccine Program

14. Regeneron Anticipates the Initiation of Clinical Study for its COVID-19 Antibody Cocktail in June

Published:  May 05, 2020 | Tags: Regeneron, Anticipates, Initiation, Clinical Study, COVID-19, Antibody Cocktail, June

15. NeoGenomics Collaborates with Bayer to Provide NTRK Testing for Patients with Colorectal and Thyroid Cancer

Published: May 05, 2020 | Tags: NeoGenomics, Collaborate, Bayer, Provide, NTRK Testing, Colorectal, Thyroid Cancer Patients 

16. Pfizer and BioNTech Report First Patient Dosing with BNT162 in P-I/II Study for COVID-19 in the US

Published: May 05, 2020 | Tags: Pfizer, BioNTech, Reports, First Patient Dosing, P-I/II, Study, BNT162, COIVD-19, US

17.  Bio-Rad Receives the US FDA’s Emergency Use Authorization for its Droplet Digital PCR Test Kit to Detect COVID-19

Published: May 04, 2020 | Tags: Bio-Rad, Receives, US, FDA, Emergency Use Authorization, Droplet Digital PCR Test Kit, Detect, COVID-19

18. Alexion to Acquire Portola for ~$1.41B

Published: May 05, 2020 | Tags: Alexion, Acquire, Portola, Expand, Commercial Portfolio, $1.14B

19. Vir and Alnylam Anticipate the Initiation of Clinical Study Assessing VIR-2703 By the Year End

Published: May 04, 2020 | Tags: Vir, Alnylam, Anticipate, Initiation, Clinical Study, Assessing, VIR-2703, By the Year End

20. Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the Treatment of COVID-19

Published:  May 04, 2020 | Tags:  Lilly, Junshi, Collaborate, Co-Develop, Antibody Therapies, Treatment, COVID-19

21. Teva and Celltrion Launch Truxima (biosimilar, rituximab) to Treat Wegener’s Granulomatosis and Microscopic Polyangiitis in the US

Published: May 04, 2020 | Tags: Teva, Celltrion, Launch, Truxima, biosimilar, rituximab, Treat, Wegener’s Granulomatosis, Microscopic Polyangiitis, US

22. Roche Receives FDA’s Emergency Use Authorization for its Elecsys to Detect COVID-19

Published: May 03, 2020 | Tags: Roche, Receives, FDA, Emergency Use Authorization, Elecsys, COVID-19

23. MHLW Expedites the Reviews of Gilead’s Remdesivir to Treat Patients with COVID-19 in Japan

Published: May 04, 2020 | Tags: MHLW, Expedites, Reviews, Gilead, Remdesivir, Treat, Patients, COIVD-19, Japan

24.  Revance and Mylan to Extend Biosimilar to BOTOX Program Decision Beyond April 30, 2020

Published: May 01, 2020 | Tags: Revance, Mylan, Extend, Biosimilar, BOTOX, Program Decision, Beyond, April 30, 2020

25.  Gilead’s Remdesivir Receives the US FDA’s Emergency Use Authorization for the Treatment of COVID-19

Published: May 01, 2020 | Tags: Gilead, Remdesivir, Receives, US, FDA, Emergency Use Authorization, Treatment, COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post